阿帕替尼单药治疗晚期结肠癌的疗效与安全性研究  

EFFICACY AND SAFETY OF APATINIB MONOTHERAPY FOR ADVANCED COLON CANCER

作　　者：李义慧[1] 刘媛媛 周洋 王晓红[2] 王建功[1] 杨俊泉[2] Li Yihui;Liu Yuanyuan;Zhou Yang(Department of Comprehensive Treatment of Tumor,Tangshan Peopled Hospital,Tangshan 063000,China)

机构地区：[1]河北省唐山市人民医院肿瘤综合治疗一科,063000 [2]河北省唐山市人民医院放化科,063000

出　　处：《中国煤炭工业医学杂志》2020年第2期138-142,共5页Chinese Journal of Coal Industry Medicine

基　　金：河北省医学科学研究重点课题计划(编号:20181208)。

摘　　要：目的回顾性分析阿帕替尼单药在晚期多线治疗失败的结肠癌中的疗效和安全性。方法选取2016年3月-2017年9月在唐山市人民医院收治的58例晚期多线治疗失败的结肠癌患者。观察组32例,予以阿帕替尼单药治疗,对照组26例,给予卡培他滨单药化疗,评价患者的客观缓解率(ORR),疾病控制率(DCR)和无进展生存期(PFS),以及患者的不良反应情况。结果观察组患者的客观缓解率为12.5%,疾病控制率为78.1%,中位无进展生存期为3.2个月。对照组患者的客观缓解率为7.7%,疾病控制率为42.3%,中位无进展生存期为2.2个月。观察组疾病控制率优于对照组(P=0.005),且中位无进展生存期长于对照组(P=0.010)。患者不良反应主要为高血压、疲乏、出血、手足综合征,恶心、呕吐、粒细胞减少等,多为1~2级不良反应,不良反应可控。与对照组比较,观察组并未加重患者不良反应。结论阿帕替尼单药治疗晚期结肠癌具有较好的疗效和安全性,可作为晚期多线治疗失败的晚期结肠癌患者的新的选择和策略。Objective To explore the clinical effects and safety of apatinib monotherapy for advanced colon cancer which failed in multi-line treatment.Methods From March 2016 to September 2017,fifty-eight advanced colon cancer patients who failed in multi-line treatment in Tangshan People′s Hospital were enrolled.32 patients in observation group were treated with apatinib monotherapy and 26 patients in control group were treated with capecitabine.The objective response rate(ORR),disease control rate(DCR)and progression-free survival(PFS)as well as the adverse events of the patients were evaluated.Results In observation group,the objective response rate was 12.5%,disease control rate was 78.1%,and median progression-free survival was 3.2 months.While in control group,the objective response rate was 7.7%,disease control rate was 42.3%,and median progression-free survival was 2.2 months.Compared with the control group,disease control rate in the observation group was better(P=0.005)and the median progression-free was longer(P=0.010).Major adverse events were hypertension,fatigue,bleeding,hand and foot syndrome,nausea,vomiting,granulocytopenia,etc,most of them were grade 1-2 adverse reactions,which were mild and controllable.Compared with the control group,the observation group did not aggravate the adverse reactions.Conclusion Apatinib has a good efficacy and safety in the treatment of advanced colon cancer,and it can be used as a new choice and strategy for patients with advanced colon cancer who failed in the multi-line treatment.

关 键 词：阿帕替尼 晚期结肠癌 临床疗效 安全性 

分 类 号：R735.3[医药卫生—肿瘤]